Quality of life in fit elderly patients with chronic lymphocytic leukemia (CLL) receiving oral fludarabine-based regimens as first line therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial.

被引：0
|
作者：
Sandhu, Suneet [1 ,2 ]
Gill, Devinder [1 ,2 ]
Turner, Paul [1 ,2 ]
Renwick, William [1 ,2 ]
Latimer, Maya [1 ,2 ]
Mackinlay, Naomi [1 ,2 ]
Berkahn, Leanne [1 ,2 ]
Simpson, David [1 ,2 ]
Campbell, Phillip [1 ,2 ]
Forsyth, Cecily [1 ,2 ]
Cull, Gavin [1 ,2 ]
Harrup, Rosemary [1 ,2 ]
Sulda, Melanie [1 ,2 ]
Best, Giles [1 ,2 ]
Bressel, Mathias [1 ,2 ]
Di Iulio, Juliana [1 ,2 ]
Kuss, Bryone [1 ,2 ]
Mulligan, Stephen [1 ,2 ]
机构：
[1] Australasian Leukaemia & Lymphoma Grp, Richmond, Vic, Australia
[2] Chron Lymphocyt Leukemia Australian Res Consortiu, Richmond, Vic, Australia
来源：
LEUKEMIA & LYMPHOMA | 2015年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
34
引用
收藏
页码：27 / 29
页数：3
相关论文
共 32 条
  • [1] Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial
    Sandhu, Suneet
    Gill, Devinder
    Turner, Paul David
    Renwick, William E. P.
    Latimer, Maya
    Mackinlay, Naomi
    Berkahn, Leanne
    Simpson, David R.
    Campbell, Philip
    Forsyth, Cecily
    Cull, Gavin
    Harrup, Rosemary
    Best, Giles
    Bressel, Mathias
    Di Iulio, Juliana
    Kuss, Bryone Jean
    Mulligan, Stephen
    BLOOD, 2015, 126 (23)
  • [2] Genomic Profiling In Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (ALLG CLL5 OFOCIR trial) As Initial Treatment Of Chronic Lymphocytic Leukemia (CLL)
    Badoux, Xavier
    Best, Giles
    Gabrielli, Sara
    Zhu, Ying
    Hayes, Melanie
    Kuss, Bryone J.
    Stevenson, William
    Mulligan, Stephen P.
    BLOOD, 2013, 122 (21)
  • [3] Molecular profiling of elderly patients receiving frontline fludarabine-based chemoimmunotherapy in the ALLG CLL5 study
    Badoux, Xavier
    Mulligan, Stephen
    Gabrielli, Sara
    Zhu, Ying
    Bressel, Mathias
    Best, Giles
    Hayes, Melanie
    Di Iulio, Juliana
    Kuss, Bryone
    LEUKEMIA & LYMPHOMA, 2015, 56 : 120 - 121
  • [4] The Safety and Tolerability of Oral Fludarabine, ±oral Cyclophosphamide and Iv Rituximab Therapy In Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years - Interim Analysis From the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study
    Mulligan, Stephen P.
    Gill, Devinder S.
    Renwick, William E. P.
    Sulda, Melanie L.
    Best, O. Giles
    Kuss, Bryone J.
    Seymour, John F.
    BLOOD, 2010, 116 (21) : 308 - 308
  • [5] Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial
    Do, Cuc
    Best, O. Giles
    Thurgood, Lauren
    Hotinski, Anya
    Apostolou, Sinoula
    Mulligan, Stephen P.
    Lower, Karen
    Kuss, Bryone
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (03) : 556 - 560
  • [6] A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years - End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study
    Mulligan, Stephen P.
    Gill, Devinder S.
    Turner, Paul
    Renwick, William E. P.
    Harrup, Rosemary
    Latimer, Maya
    Mackinlay, Naomi
    Berkahn, Leanne
    Simpson, David
    Campbell, Philip
    Tiley, Campbell
    Cull, Gavin
    Collins, Marnie
    Cortissos, Paul
    Sulda, Melanie
    Best, Giles
    Kuss, Bryone J.
    BLOOD, 2012, 120 (21)
  • [7] Detailed long-term follow-up of treatment-nayve chronic lymphocytic leukemia (CLL) patients in the Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial; data on 17 (15% of total cohort) patients from a single-institution
    Sandhu, Suneet
    Mackinlay, Naomi
    Coyle, Luke
    Best, Giles
    Mulligan, Stephen
    LEUKEMIA & LYMPHOMA, 2015, 56 : 29 - 31
  • [8] Detailed Long-Term Follow up of Treatment-Naive Chronic Lymphocytic Leukemia (CLL) Patients in the Australasian Leukemia and Lymphoma Group (ALLG) CLL5 Trial; Data on 17 (15% of Total Cohort) Patients from a Single-Institution
    Sandhu, Suneet
    Mackinlay, Naomi
    Coyle, Luke
    Best, Giles
    Mulligan, Stephen
    BLOOD, 2015, 126 (23)
  • [9] Phase II Trial of Ofatumumab (OFA) for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
    Flinn, Ian W.
    Harwin, William N.
    Ward, Patrick
    Doss, Habib H.
    Papish, Steven W.
    Hainsworth, John D.
    Berdeja, Jesus G.
    Byrd, John C.
    BLOOD, 2012, 120 (21)
  • [10] Molecular and Genetic Characterization of Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As Initial Treatment of Chronic Lymphocytic Leukemia (CLL)
    Badoux, Xavier C.
    Best, Giles
    Gabrielli, Sara
    Hayes, Melanie
    Zhu, Ying
    Mulligan, Stephen
    Kuss, Bryone J.
    BLOOD, 2014, 124 (21)
1234